Investors | Syncona

Unless stated all financials at 30 September 2024

£1.1bn

Net assets

179p

NAV per share

(5.2)%

NAV per share return in the year

£792m

Value of life science portfolio

(8.8)%

Return from life science portfolio in the year

£353m

Capital pool

Transaction in Own Shares

21.11.24

Transaction in Own Shares

20.11.24

Board Committee Change

19.11.24

Transaction in Own Shares

19.11.24

Transaction in Own Shares

18.11.24

Transaction in Own Shares

15.11.24

Half-year Report

14.11.24

Syncona launches Slingshot Therapeutics

14.11.24

Transaction in Own Shares

14.11.24

Transaction in Own Shares

13.11.24

Autolus reports Q3 2024 Financial Results

12.11.24

Transaction in Own Shares

12.11.24

Transaction in Own Shares

11.11.24

Autolus receives US FDA approval

11.11.24

Transaction in Own Shares

08.11.24

Transaction in Own Shares

07.11.24

Transaction in Own Shares

06.11.24

Transaction in Own Shares

05.11.24